The U.S. military will begin screening all service members age 30 and older for low testosterone levels starting later this year [1].
This initiative marks a significant shift in military health policy by targeting hormonal health as a component of operational readiness. The program aims to improve the overall health of troops, and simplify the process for those who may benefit from hormone therapy [2].
Defense Secretary Pete Hegseth said the policy on July 15, 2026 [1]. Under the new guidelines, any service member 30 years or older [1] will undergo screening, a requirement that includes women in the program [1]. For those who test low, the administration said that receiving hormone therapy will be voluntary [1].
Beyond the military, prescription testosterone remains available to adult men across the United States who are diagnosed with low testosterone by a licensed healthcare provider [3]. Current administration proposals suggest a goal of simplifying the prescribing process for civilian men who could benefit from the medication [2].
While the primary objective is to treat clinically low levels, the rollout has sparked discussions regarding the implications of widespread hormonal screening within the ranks. The program will be implemented across all U.S. military installations to ensure consistent access to testing and potential treatment [4].
Medical providers will continue to oversee the administration of these therapies to ensure patient safety, and adherence to clinical guidelines [3]. The integration of this screening into standard military health checks reflects a broader effort to optimize the physical performance and well-being of the force [2].
“The program aims to improve the overall health of troops and simplify the process for those who may benefit from hormone therapy.”
The introduction of mandatory hormonal screening for a broad age bracket of military personnel suggests the Department of Defense is increasingly viewing endocrine health as a critical factor in combat readiness. By including women in the screening and keeping treatment voluntary, the military is attempting to balance a systemic health push with individual medical autonomy, while the parallel civilian proposals indicate a potential broader shift toward easier access to hormone replacement therapy across the U.S. healthcare system.
